| 1 |
Functional and physical interaction between Bcl‐XL and a BH3‐like domain in Beclin‐1
Maria Chiara Maiuri, Gaëtane Le Toumelin, Alfredo Criollo et al. · The EMBO Journal
Open access |
19 Apr 2007 |
1,095 |
| 2 |
The MCL1 inhibitor S63845 is tolerable and effective in diverse cancer models
András Kotschy et al. · Nature
|
Oct 2016 |
1,079 |
| 3 |
The neurobiology and control of anxious states
Mark John Millan · Progress in Neurobiology
|
Jun 2003 |
971 |
| 4 |
Promoting the clearance of neurotoxic proteins in neurodegenerative disorders of ageing
Barry Boland, Wai Haung Yu, Olga Corti et al. · Nature Reviews Drug Discovery
ReviewOpen access |
17 Aug 2018 |
570 |
| 5 |
Multi-target strategies for the improved treatment of depressive states: Conceptual foundations and neuronal substrates, drug discovery and therapeutic application
Mark J. Millan · Pharmacology & Therapeutics
|
May 2006 |
548 |
| 6 |
The Novel Melatonin Agonist Agomelatine (S20098) Is an Antagonist at 5-Hydroxytryptamine2C Receptors, Blockade of Which Enhances the Activity of Frontocortical Dopaminergic and Adrenergic Pathways
Mark John Millan, Alain P. Gobert, Françoise Lejeune et al. · Journal of Pharmacology and Experimental Therapeutics
Open access |
19 Aug 2003 |
517 |
| 7 |
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. I. A Multivariate Analysis of the Binding Profiles of 14 Drugs at 21 Native and Cloned Human Receptor Subtypes
Mark J. Millan, Lisa Maiofiss, Didier Cussac et al. · Journal of Pharmacology and Experimental Therapeutics
Open access |
2002 |
487 |
| 8 |
BH3-Only Proteins and BH3 Mimetics Induce Autophagy by Competitively Disrupting the Interaction between Beclin 1 and Bcl-2/Bcl-XL
Maria Chiara Maiuri, Alfredo Criollo, Ezgi Tasdemir et al. · Autophagy
Open access |
16 Jul 2007 |
428 |
| 9 |
Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies
Reuben Benjamin et al. · The Lancet
Open access140 authors |
Dec 2020 |
375 |
| 10 |
Network‐based Approaches in Pharmacology
Baptiste Boezio, Karine Audouze, Pierre Ducrot et al. · Molecular Informatics
Open access |
10 Jul 2017 |
374 |
| 11 |
Serotonin2C receptors tonically suppress the activity of mesocortical dopaminergic and adrenergic, but not serotonergic, pathways: A combined dialysis and electrophysiological analysis in the rat
Alain P. Gobert, Jean‐Michel Rivet, Fran�oise Lejeune et al. · Synapse
|
Jun 2000 |
339 |
| 12 |
(1-(2,5-dimethoxy-4 iodophenyl)-2-aminopropane)-induced head-twitches in the rat are mediated by 5-hydroxytryptamine (5-HT) 2A receptors: modulation by novel 5-HT2A/2C antagonists, D1 antagonists and 5-HT1A agonists.
Robert D. Schreiber, Mauricette Brocco, Valérie Audinot et al. · Journal of Pharmacology and Experimental Therapeutics
|
Apr 1995 |
301 |
| 13 |
Improving the Treatment of Schizophrenia: Focus on Serotonin (5-HT)1A Receptors
Mark J. Millan · Journal of Pharmacology and Experimental Therapeutics
|
Dec 2000 |
287 |
| 14 |
Serotonin (5-HT)2C receptors tonically inhibit dopamine (DA) and noradrenaline (NA), but not 5-HT, release in the frontal cortex in vivo
Mark John Millan, Anne Dekeyne, Alain P. Gobert · Neuropharmacology
|
Jul 1998 |
285 |
| 15 |
The role of monoamines in the actions of established and “novel” antidepressant agents: a critical review
Mark John Millan · European Journal of Pharmacology
|
18 Aug 2004 |
256 |
| 16 |
Anxiolytic properties of agomelatine, an antidepressant with melatoninergic and serotonergic properties: role of 5-HT2C receptor blockade
Mark John Millan, Mauricette Brocco, Alain P. Gobert et al. · Psychopharmacology
|
30 Jul 2004 |
250 |
| 17 |
Conidial Hydrophobins ofAspergillus fumigatus
Sophie Paris, Jean-Paul Debeaupuis, Reto Crameri et al. · Applied and Environmental Microbiology
Open access |
Mar 2003 |
242 |
| 18 |
Dopamine D3 receptor antagonists as therapeutic agents
Jeffrey N. Joyce, Mark John Millan · Drug Discovery Today
|
Jul 2005 |
238 |
| 19 |
Autotaxin Is Released from Adipocytes, Catalyzes Lysophosphatidic Acid Synthesis, and Activates Preadipocyte Proliferation
Gilles Ferry, Edwige Tellier, Anne Try et al. · Journal of Biological Chemistry
Open access |
May 2003 |
234 |
| 20 |
Src kinase phosphorylates vascular endothelial-cadherin in response to vascular endothelial growth factor: identification of tyrosine 685 as the unique target site
Yann Wallez, Francine Cand, Francisco H. Cruzalegui et al. · Oncogene
|
14 Aug 2006 |
232 |
| 21 |
An epigenetic framework for neurodevelopmental disorders: From pathogenesis to potential therapy
Mark John Millan · Neuropharmacology
|
11 Dec 2012 |
231 |
| 22 |
Reciprocal autoreceptor and heteroreceptor control of serotonergic, dopaminergic and noradrenergic transmission in the frontal cortex: relevance to the actions of antidepressant agents
Mark John Millan, Franćoise Lejeune, Alain P. Gobert · Journal of Psychopharmacology
|
Mar 2000 |
230 |
| 23 |
N-Methyl-d-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives
Mark John Millan · Psychopharmacology
|
10 Mar 2005 |
222 |
| 24 |
Differential pharmacological in vitro properties of organic cation transporters and regional distribution in rat brain
Anne Amphoux, Vincent Vialou, Eva Drescher et al. · Neuropharmacology
|
Apr 2006 |
214 |
| 25 |
Neuroprotective and anti-amnesic potentials of sigma (σ) receptor ligands
Tangui Maurice, Brian Paul Lockhart · Progress in Neuro-Psychopharmacology and Biological Psychiatry
|
1997 |
211 |
| 26 |
Simultaneous quantification of serotonin, dopamine and noradrenaline levels in single frontal cortex dialysates of freely-moving rats reveals a complex pattern of reciprocal auto- and heteroreceptor-mediated control of release
Alain P. Gobert, Jean‐Michel Rivet, Valérie Audinot et al. · Neuroscience
|
Feb 1998 |
204 |
| 27 |
Integrins: Molecular targets in cancer therapy
Gordon C. Tucker · Current Oncology Reports
|
Apr 2006 |
204 |
| 28 |
Agonist and antagonist actions of yohimbine as compared to fluparoxan at ?2-adrenergic receptors (AR)s, serotonin (5-HT)1A, 5-HT1B, 5-HT1D and dopamine D2 and D3 receptors. Significance for the modulation of frontocortical monoaminergic transmission and depressive states
Mark J. Millan, Adrian Newman‐Tancredi, Val�rie Audinot et al. · Synapse
Open access |
Feb 2000 |
198 |
| 29 |
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. III. Agonist and Antagonist Properties at Serotonin, 5-HT1 and 5-HT2, Receptor Subtypes
Adrian Newman‐Tancredi, Didier Cussac, Yann Quentric et al. · Journal of Pharmacology and Experimental Therapeutics
|
2002 |
196 |
| 30 |
Synergistic action of the MCL-1 inhibitor S63845 with current therapies in preclinical models of triple-negative and HER2-amplified breast cancer
Delphine Mérino et al. · Science Translational Medicine
|
2 Aug 2017 |
194 |
| 31 |
Glial D-Serine Gates NMDA Receptors at Excitatory Synapses in Prefrontal Cortex
Pascal Fossat, Fabrice R. Turpin, Silvia Sacchi et al. · Cerebral Cortex
Open access |
20 Jun 2011 |
186 |
| 32 |
Differential Actions of Antiparkinson Agents at Multiple Classes of Monoaminergic Receptor. II. Agonist and Antagonist Properties at Subtypes of Dopamine D2-Like Receptor and α1/α2-Adrenoceptor
Adrian Newman‐Tancredi, Didier Cussac, Valérie Audinot et al. · Journal of Pharmacology and Experimental Therapeutics
|
2002 |
182 |
| 33 |
Physical interaction between the serotonin transporter and neuronal nitric oxide synthase underlies reciprocal modulation of their activity
Benjamin Chanrion, Clotilde Mannoury la Cour, Federica Bertaso et al. · Proceedings of the National Academy of Sciences
Open access |
24 Apr 2007 |
181 |
| 34 |
Combining BH3-mimetics to target both BCL-2 and MCL1 has potent activity in pre-clinical models of acute myeloid leukemia
Donia M. Moujalled et al. · Leukemia
Open access |
10 Sep 2018 |
176 |
| 35 |
Mechanisms Contributing to the Phase-Dependent Regulation of Neurogenesis by the Novel Antidepressant, Agomelatine, in the Adult Rat Hippocampus
Amélie Soumier, Mounira Banasr, Sylviane Lortet et al. · Neuropsychopharmacology
|
Jul 2009 |
175 |
| 36 |
TTK/hMPS1 Is an Attractive Therapeutic Target for Triple-Negative Breast Cancer
Virginie Maire, Céline Baldeyron, Marion Richardson et al. · PLoS ONE
Open access |
20 May 2013 |
175 |
| 37 |
Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties
Béatrice Guardiola-Lemaı̂tre, Christian de Bodinat, Philippe Delagrange et al. · British Journal of Pharmacology
Open access |
14 Apr 2014 |
175 |
| 38 |
Comparison of MF/UF pretreatment with conventional filtration prior to RO membranes for surface seawater desalination
Anne Brehant, Véronique Bonnelye, M. Perez · Desalination
|
Sep 2002 |
174 |
| 39 |
Serotonin (5-HT)2A receptor activation enhances dialysate levels of dopamine and noradrenaline, but not 5-HT, in the frontal cortex of freely-moving rats
Alain P. Gobert, Mark John Millan · Neuropharmacology
|
Feb 1999 |
171 |
| 40 |
Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of α2‐adrenergic and serotonin2C receptors: a comparison with citalopram
Mark John Millan, Alain P. Gobert, Jean‐Michel Rivet et al. · European Journal of Neuroscience
|
Mar 2000 |
170 |
| 41 |
Selective Blockade of Dopamine D3 Receptors Enhances while D2 Receptor Antagonism Impairs Social Novelty Discrimination and Novel Object Recognition in Rats: A Key Role for the Prefrontal Cortex
David J. Watson, Florence Loiseau, Manuela Ingallinesi et al. · Neuropsychopharmacology
Open access |
26 Oct 2011 |
156 |
| 42 |
The Vogel conflict test: procedural aspects, γ-aminobutyric acid, glutamate and monoamines
Mark John Millan, Mauricette Brocco · European Journal of Pharmacology
|
Feb 2003 |
151 |
| 43 |
Bax activation by the BH3-only protein Puma promotes cell dependence on antiapoptotic Bcl-2 family members
Tristan Gallenne, Fabien Gautier, Lisa J. Oliver et al. · The Journal of Cell Biology
Open access |
20 Apr 2009 |
146 |
| 44 |
Contrasting mechanisms of action and sensitivity to antipsychotics of phencyclidine versus amphetamine: importance of nucleus accumbens 5‐HT2A sites for PCP‐induced locomotion in the rat
Mark John Millan, Mauricette Brocco, Alain P. Gobert et al. · European Journal of Neuroscience
|
Dec 1999 |
139 |
| 45 |
Multiple alpha-2 adrenergic receptor subtypes. II. Evidence for a role of rat R alpha-2A adrenergic receptors in the control of nociception, motor behavior and hippocampal synthesis of noradrenaline.
Mark J. Millan, Karin J. W. Bervoets, Jean‐Michel Rivet et al. · Journal of Pharmacology and Experimental Therapeutics
|
Sep 1994 |
138 |
| 46 |
The "selective" dopamine D 1 receptor antagonist, SCH23390, is a potent and high efficacy agonist at cloned human serotonin 2C receptors
Mark John Millan, Adrian Newman‐Tancredi, Yann Quentric et al. · Psychopharmacology
|
Jun 2001 |
134 |
| 47 |
Potentiation of the Fluoxetine‐Induced Increase in Dialysate Levels of Serotonin (5‐HT) in the Frontal Cortex of Freely Moving Rats by Combined Blockade of 5‐HT1A and 5‐HT1B Receptors with WAY 100,635 and GR 127,935
Alain P. Gobert, Jean‐Michel Rivet, Laetitia Cistarelli et al. · Journal of Neurochemistry
|
Mar 1997 |
134 |
| 48 |
Blockade of the discriminative stimulus effects of DOI by MDL 100,907 and the ‘atypical’ antipsychotics, clozapine and risperidone
Rudy Schreiber, Mauricette Brocco, Mark J. Millan · European Journal of Pharmacology
|
Oct 1994 |
129 |
| 49 |
Blockade of phencyclidine-induced hyperlocomotion by clozapine and MDL 100,907 in rats reflects antagonism of 5-HT2A receptors
Sophie Maurel-Remy, Karin J. W. Bervoets, Mark John Millan · European Journal of Pharmacology
|
Jul 1995 |
128 |
| 50 |
Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)-S 14297: 1. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy.
Mark J. Millan, J.‐L. PEGLION, Joël Vian et al. · Journal of Pharmacology and Experimental Therapeutics
|
Nov 1995 |
126 |